Reproductive function and pregnancy outcomes in women treated for idiopathic hyperprolactinemia: A non-randomized controlled study

Publish Year: 1399
نوع سند: مقاله ژورنالی
زبان: English
View: 174

This Paper With 10 Page And PDF Format Ready To Download

  • Certificate
  • من نویسنده این مقاله هستم

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این Paper:

شناسه ملی سند علمی:

JR_IJRM-18-12_004

تاریخ نمایه سازی: 17 فروردین 1400

Abstract:

Background: Few studies have focused to determine the peculiarities of the course of pregnancy and pregnancy outcomes after treatment in women with idiopathic hyperprolactinemia. Objective: To determine the peculiarities of the course of pregnancy and pregnancy outcomes in women treated for idiopathic hyperprolactinemia, with history of infertility and/or recurrent pregnancy loss. Materials and Methods: A non-randomized controlled study was conducted at the Center for Reproductive Medicine "Universe" and Medical Clinic “Medhealth” during 2016-2018, involving 96 women with idiopathic hyperprolactinemia, aged 20-44 yr with infertility and/or a history of recurrent pregnancy loss. Prolactin (PRL), follicle-stimulating hormone, luteinizing hormone, estradiol (E2), free testosterone, and progesterone were studied in blood serum using immunoassay analysis method. Before the occurrence of pregnancy, hyperprolactinemia was treated with bromocriptine. Dydrogesterone was used to support the luteal phase. Results: PRL levels decreased significantly and normalized within two-five months, regular menstrual cycle was restored in two-four months, ovulation was restored in three-seven months, and pregnancy was achieved in three-fourteen months. E2 and progesterone levels increased significantly (p < 0.001). Prior to the treatment, significant negative correlation between PRL and E2 (r = -0.386, p = 0.007), PRL and progesterone (r = -0.420, p = 0.003) was detected. Threatened early abortion prevailed among pregnancy complications. Pregnancy loss in the first trimester was recorded in 3.12% of cases. Conclusion: Pregnancy outcomes in women with idiopathic hyperprolactinemia are improved by prolonged and continuous treatment with bromocriptine before pregnancy and administration of dydrogesterone in support of the luteal insufficiency.

Authors

Khatuna Sokhadze

Faculty of Medicine, Ivane Javakhishvili Tbilisi State University, Tbilisi, Georgia.

Sophio Kvaliashvili

Medical Clinic “Health House”, Tbilisi, Georgia.

Jenaro Kristesashvili

Center for Reproductive Medicine “Universe”, Tbilisi, Georgia.

مراجع و منابع این Paper:

لیست زیر مراجع و منابع استفاده شده در این Paper را نمایش می دهد. این مراجع به صورت کاملا ماشینی و بر اساس هوش مصنوعی استخراج شده اند و لذا ممکن است دارای اشکالاتی باشند که به مرور زمان دقت استخراج این محتوا افزایش می یابد. مراجعی که مقالات مربوط به آنها در سیویلیکا نمایه شده و پیدا شده اند، به خود Paper لینک شده اند :
  • Saleem M, Martin H, Coates P. Prolactin biology and laboratory ...
  • Crosignani PG. Management of hyperprolactinemic infertility. Middle East Fertility Society ...
  • Vander Borght M, Wyns Ch. Fertility and infertility: Definition and ...
  • Majumdar A, Mangal NS. Hyperprolactinemia. J Hum Reprod Sci 2013; ...
  • El Hachem H, Crepaux V, May-Panloup P, Descamps P, Legendre ...
  • Arredondo F, Noble LS. Endocrinology of recurrent pregnancy loss. Semin ...
  • Kaur R, Gupta K. Endocrine dysfunction and recurrent spontaneous abortion: ...
  • Palomba S, Santagni S, La Sala GB. Progesterone administration for ...
  • Glezer A, Bronstein MD. Approach to the patient with persistent ...
  • Adra A, El Zibdeh MY, Abdul Malek AMM, Hamrahian AH, ...
  • Goyal A, Ganie MA. Idiopathic hyperprolactinemia presenting as polycystic ovary ...
  • Chen H, Fu J, Huang W. Dopamine agonists for preventing ...
  • Hirahara F, Andoh N, Sawai K, Hirabuki T, Uemura T, ...
  • Passos VQ, Souza JJ, Musolino NR, Bronstein MD. Long-term follow-up ...
  • Hekimsoy Z, Kafesciler S, Guclu F, Ozmen B. The prevalence ...
  • Turankar S, Sonone K, Turankar A. Hyperprolactinemia and its comparision ...
  • Kulshreshtha B, Pahuja I, Kothari D, Chawla I, Sharma N, ...
  • Lee DY, Oh YK, Yoon BK, Choi D. Prevalence of ...
  • Molitch ME. Endocrinology in pregnancy: management of the pregnant patient ...
  • Carp H. A systematic review of dydrogesterone for the treatment ...
  • Carp H. A systematic review of dydrogesterone for the treatment ...
  • Kumar A, Begun N, Prasad S, Aggarwal S, Sharma S. ...
  • Mirza FG, Patki A, Pexman-Fieth C. Dydrogesterone use in early ...
  • Dante G, Vaccaro V, Facchinetti F. Use of progestagens during ...
  • Saleem M, Martin H, Coates P. Prolactin biology and laboratory ...
  • Crosignani PG. Management of hyperprolactinemic infertility. Middle East Fertility Society ...
  • Vander Borght M, Wyns Ch. Fertility and infertility: Definition and ...
  • Majumdar A, Mangal NS. Hyperprolactinemia. J Hum Reprod Sci 2013; ...
  • El Hachem H, Crepaux V, May-Panloup P, Descamps P, Legendre ...
  • Arredondo F, Noble LS. Endocrinology of recurrent pregnancy loss. Semin ...
  • Kaur R, Gupta K. Endocrine dysfunction and recurrent spontaneous abortion: ...
  • Palomba S, Santagni S, La Sala GB. Progesterone administration for ...
  • Glezer A, Bronstein MD. Approach to the patient with persistent ...
  • Adra A, El Zibdeh MY, Abdul Malek AMM, Hamrahian AH, ...
  • Goyal A, Ganie MA. Idiopathic hyperprolactinemia presenting as polycystic ovary ...
  • Chen H, Fu J, Huang W. Dopamine agonists for preventing ...
  • Hirahara F, Andoh N, Sawai K, Hirabuki T, Uemura T, ...
  • Passos VQ, Souza JJ, Musolino NR, Bronstein MD. Long-term follow-up ...
  • Hekimsoy Z, Kafesciler S, Guclu F, Ozmen B. The prevalence ...
  • Turankar S, Sonone K, Turankar A. Hyperprolactinemia and its comparision ...
  • Kulshreshtha B, Pahuja I, Kothari D, Chawla I, Sharma N, ...
  • Lee DY, Oh YK, Yoon BK, Choi D. Prevalence of ...
  • Molitch ME. Endocrinology in pregnancy: management of the pregnant patient ...
  • Carp H. A systematic review of dydrogesterone for the treatment ...
  • Carp H. A systematic review of dydrogesterone for the treatment ...
  • Kumar A, Begun N, Prasad S, Aggarwal S, Sharma S. ...
  • Mirza FG, Patki A, Pexman-Fieth C. Dydrogesterone use in early ...
  • Dante G, Vaccaro V, Facchinetti F. Use of progestagens during ...
  • نمایش کامل مراجع